Last 12 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.17 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 1.18 | 4.30 | 2.35 | 2.31 | 2.14 | 1.16 | 1.55 | 1.93 | 2.72 | — | — | — | — |
| — | +269.5% | +52.0% | +19.9% | -21.3% | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -30.9% | -11.3% | -12.3% | -9.3% | -8.7% | -6.1% | -7.8% | -4.2% | -10.4% | -192.4% | -6.1% | -12.4% | — |
| — | -84.2% | -58.5% | -122.1% | +17.0% | +96.8% | -27.3% | +66.1% | — | — | — | — | — | |
| ROA | -27.6% | -10.4% | -11.4% | -8.7% | -8.3% | -5.9% | -7.0% | -3.8% | -4.8% | -8.2% | -5.6% | -5.3% | — |
| — | -76.9% | -62.3% | -127.9% | -73.4% | +28.0% | -24.5% | +27.9% | — | — | — | — | — | |
| ROIC | -75.4% | -15.9% | -18.1% | -11.4% | -26.1% | -2900.2% | -16281.0% | -688.4% | — | — | — | — | — |
| — | +99.5% | +99.9% | +98.3% | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — |
| — | -51.8% | +117.7% | +184.0% | +461.6% | — | -52.0% | -50.1% | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 14.58 | 11.59 | 13.85 | 14.58 | 14.14 | 25.80 | 24.62 | 27.93 | 36.01 | 12.83 | 12.83 | 15.32 | — |
| — | -55.1% | -43.7% | -47.8% | -60.7% | +101.1% | +91.9% | +82.4% | — | — | — | — | — | |
| Quick Ratio | 14.58 | 11.59 | 13.85 | 14.58 | 14.14 | 25.80 | 24.62 | 27.93 | 36.01 | 12.83 | 12.83 | 15.32 | — |
| — | -55.1% | -43.7% | -47.8% | -60.7% | +101.1% | +91.9% | +82.4% | — | — | — | — | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 12 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BCAX stock.
Bicara Therapeutics Inc. Common Stock's current P/E is -3.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Bicara Therapeutics Inc. Common Stock's business trajectory between earnings reports.